作者
Kathleen M. Sullivan,Marta Vilalta,Linda Ertl,Yu Wang,Carolyn Dunlap,Karen Ebsworth,Bin Zhao,Shijie Li,Yibin Zeng,Zhenhua Miao,Pingchen Fan,Venkat Mali,Christopher S. Lange,Darren McMurtrie,Ju Yang,Rebecca Lui,Ryan J. Scamp,Vicky Chhina,Alice Kumamoto,Simon Yau,Ton Dang,Ashton Easterday,Shirley Liu,Shichang Miao,Israel F. Charo,Thomas J. Schall,Penglie Zhang
摘要
The interaction of PD-L1 with PD-1 is a major immune checkpoint that limits effector T cell function against cancer cells; monoclonal antibodies that block this pathway have been approved in multiple tumor indications. As a next generation therapy, small molecule inhibitors of PD-L1 have inherent drug properties that may be advantageous for certain patient populations compared to antibody therapies. In this report we present the pharmacology of the orally-available, small molecule PD-L1 inhibitor CCX559 for cancer immunotherapy. CCX559 potently and selectively inhibited PD-L1 binding to PD-1 and CD80 in vitro, and increased activation of primary human T cells in a T cell receptor-dependent fashion. Oral administration of CCX559 demonstrated anti-tumor activity similar to an anti-human PD-L1 antibody in two murine tumor models. Treatment of cells with CCX559 induced PD-L1 dimer formation and internalization, which prevented interaction with PD-1. Cell surface PD-L1 expression recovered in MC38 tumors upon CCX559 clearance post dosing. In a cynomolgus monkey pharmacodynamic study, CCX559 increased plasma levels of soluble PD-L1. These results support the clinical development of CCX559 for solid tumors; CCX559 is currently in a Phase 1, first in patient, multicenter, open-label, dose-escalation study (ACTRN12621001342808).